Fosun Tweaks Gland Deal Amid Limbo In India

China’s Fosun group isn’t backing off from its $1bn-plus buyout of Gland Pharma and will now pursue a tweaked version of the original deal that technically qualifies for automatic approval under Indian rules. Whether that means smooth sailing hereon remains unclear.

Big Fish
WILL FOSUN'S ACQUISITION OF GLAND MOVE SMOOTHLY AHEAD HEREON?

China’s Fosun group has agreed to pare its proposed holding in the Indian injectables firm Gland Pharma Ltd. as part of certain revised terms pertaining to the mega deal, currently in limbo in India.

The deal has already been cleared by India’s Foreign Investment Promotion Board (FIPB) [although the FIPB itself has since been...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip